{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:07:00Z","timestamp":1792480020234,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T00:00:00Z","timestamp":1553817600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T00:00:00Z","timestamp":1553817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1007\/s11523-019-00632-w","type":"journal-article","created":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T08:04:50Z","timestamp":1553846690000},"page":"205-221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0487-7996","authenticated-orcid":false,"given":"Emanuel","family":"Raschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Mazzarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ippazio Cosimo","family":"Antonazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Bendinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Forcesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tuccori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"De Ponti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,29]]},"reference":[{"key":"632_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11523-017-0549-7","volume":"13","author":"JM Clarke","year":"2018","unstructured":"Clarke JM, George DJ, Lisi S, Salama AKS. Immune checkpoint blockade: the new frontier in cancer treatment. Targ Oncol. 2018;13:1\u201320.","journal-title":"Targ Oncol."},{"key":"632_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11523-016-0471-4","volume":"12","author":"J Martin-Liberal","year":"2017","unstructured":"Martin-Liberal J, Hierro C, de Ochoa OM, Rodon J. Immuno-oncology: the third paradigm in early drug development. Targ Oncol. 2017;12:125\u201338.","journal-title":"Targ Oncol."},{"key":"632_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd.2015.35","volume":"15","author":"A Hoos","year":"2016","unstructured":"Hoos A. Development of immuno-oncology drugs\u2014from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15:235\u201347.","journal-title":"Nat Rev Drug Discov."},{"key":"632_CR4","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2:1346\u201353.","journal-title":"JAMA Oncol."},{"key":"632_CR5","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749\u201355.","journal-title":"N Engl J Med"},{"key":"632_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"},{"key":"632_CR7","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714\u201368.","journal-title":"J Clin Oncol"},{"key":"632_CR8","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/S1470-2045(18)30828-3","volume":"20","author":"F Martins","year":"2019","unstructured":"Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, et al. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol. 2019;20:e54\u201364.","journal-title":"Lancet Oncol."},{"key":"632_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13:473\u201386.","journal-title":"Nat Rev Clin Oncol."},{"key":"632_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11739-017-1755-0","volume":"13","author":"E Raschi","year":"2018","unstructured":"Raschi E, Diemberger I, Cosmi B, De Ponti F. ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations. Intern Emerg Med. 2018;13:1\u20139.","journal-title":"Intern Emerg Med"},{"key":"632_CR11","doi-asserted-by":"publisher","first-page":"k793","DOI":"10.1136\/bmj.k793","volume":"360","author":"S Baxi","year":"2018","unstructured":"Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018;360:k793.","journal-title":"BMJ."},{"key":"632_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/M17-2073","volume":"168","author":"N Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med. 2018;168:121\u201330.","journal-title":"Ann Intern Med"},{"key":"632_CR13","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391:933.","journal-title":"Lancet"},{"key":"632_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11523-018-0579-9","volume":"13","author":"M Ferreira","year":"2018","unstructured":"Ferreira M, Pichon E, Carmier D, Bouquet E, Pageot C, Bejan-Angoulvant T, et al. Coronary toxicities of anti-PD-1 and anti-PD-L1 immunotherapies: a case report and review of the literature and international registries. Targ Oncol. 2018;13:509\u201315.","journal-title":"Targ Oncol."},{"key":"632_CR15","doi-asserted-by":"publisher","unstructured":"Centanni M, Moes DJAR, Troconiz IF, Ciccolini J, van Hasselt JGC. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. Clin Pharmacokinet. 2019. \n                  https:\/\/doi.org\/10.1007\/s40262-019-00748-2\n                  \n                .","DOI":"10.1007\/s40262-019-00748-2"},{"key":"632_CR16","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013;10:796\u2013803.","journal-title":"Int J Med Sci."},{"key":"632_CR17","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2165\/11538330-000000000-00000","volume":"33","author":"TJ Giezen","year":"2010","unstructured":"Giezen TJ, Mantel-Teeuwisse AK, Meyboom RH, Straus SM, Leufkens HG, Egberts TC. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Drug Saf. 2010;33:865\u201378.","journal-title":"Drug Saf."},{"key":"632_CR18","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s40264-014-0224-1","volume":"37","author":"PM Cutroneo","year":"2014","unstructured":"Cutroneo PM, Isgro V, Russo A, Ientile V, Sottosanti L, Pimpinella G, et al. Safety profile of biological medicines as compared with non-biologicals: an analysis of the italian spontaneous reporting system database. Drug Saf. 2014;37:961\u201370.","journal-title":"Drug Saf"},{"key":"632_CR19","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s11523-017-0529-y","volume":"12","author":"A Gouverneur","year":"2017","unstructured":"Gouverneur A, Claraz P, Rousset M, Arnaud M, Fourrier-Reglat A, Pariente A, et al. Comparative safety of targeted therapies for metastatic colorectal cancer between elderly and younger patients: a study using the international pharmacovigilance database. Target Oncol. 2017;12:805\u201314.","journal-title":"Target Oncol."},{"key":"632_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40259-018-0285-2","volume":"32","author":"AGS Araujo","year":"2018","unstructured":"Araujo AGS, Borba HHL, Tonin FS, Lenzi L, Venson R, Pontarolo R, et al. Safety of biologics approved for the treatment of rheumatoid arthritis and other autoimmune diseases: a disproportionality analysis from the FDA adverse event reporting system (FAERS). BioDrugs. 2018;32:377\u201390.","journal-title":"BioDrugs."},{"key":"632_CR21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.numecd.2018.02.014","volume":"28","author":"E Raschi","year":"2018","unstructured":"Raschi E, Poluzzi E, Salvo F, Pariente A, De Ponti F, Marchesini G, et al. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutr Metab Cardiovasc Dis. 2018;28:533\u201342.","journal-title":"Nutr Metab Cardiovasc Dis."},{"key":"632_CR22","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/pds.4672","volume":"27","author":"C Fukazawa","year":"2018","unstructured":"Fukazawa C, Hinomura Y, Kaneko M, Narukawa M. Significance of data mining in routine signal detection: analysis based on the safety signals identified by the FDA. Pharmacoepidemiol Drug Saf. 2018;27:1402\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"632_CR23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/clpt.2013.24","volume":"93","author":"R Harpaz","year":"2013","unstructured":"Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93:539\u201346.","journal-title":"Clin Pharmacol Ther"},{"key":"632_CR24","first-page":"265","volume-title":"Data mining applications in engineering and medicine","author":"E Poluzzi","year":"2012","unstructured":"Poluzzi E, Raschi E, Piccinni C, De Ponti F. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). In: Karahoca A, editor. Data mining applications in engineering and medicine. Croatia: InTech; 2012. p. 265\u2013302."},{"key":"632_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"632_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1586\/17512433.2015.974555","volume":"8","author":"M Tuccori","year":"2015","unstructured":"Tuccori M, Montagnani S, Capogrosso-Sansone A, Mantarro S, Antonioli L, Fornai M, et al. Adverse reactions to oncologic drugs: spontaneous reporting and signal detection. Expert Rev Clin Pharmacol. 2015;8:61\u201375.","journal-title":"Expert Rev Clin Pharmacol."},{"key":"632_CR27","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40264-013-0075-1","volume":"36","author":"J Slattery","year":"2013","unstructured":"Slattery J, Alvarez Y, Hidalgo A. Choosing thresholds for statistical signal detection with the proportional reporting ratio. Drug Saf. 2013;36:687\u201392.","journal-title":"Drug Saf"},{"key":"632_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/2042098616685010","volume":"8","author":"M Hauben","year":"2017","unstructured":"Hauben M, Hung E, Wood J, Soitkar A, Reshef D. The impact of database restriction on pharmacovigilance signal detection of selected cancer therapies. Ther Adv Drug Saf. 2017;8:145\u201356.","journal-title":"Ther Adv Drug Saf."},{"key":"632_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1471-2288-11-92","volume":"11","author":"P Bragge","year":"2011","unstructured":"Bragge P, Clavisi O, Turner T, Tavender E, Collie A, Gruen RL. The Global Evidence Mapping Initiative: scoping research in broad topic areas. BMC Med Res Methodol. 2011;11:92.","journal-title":"BMC Med Res Methodol"},{"key":"632_CR30","doi-asserted-by":"publisher","unstructured":"Baraibar I, Melero I, Ponz-Sarvise M, Castanon E. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. Drug Saf. 2019. \n                  https:\/\/doi.org\/10.1007\/s40264-018-0774-8\n                  \n                .","DOI":"10.1007\/s40264-018-0774-8"},{"key":"632_CR31","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu CT, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28:2377\u201385.","journal-title":"Ann Oncol"},{"key":"632_CR32","doi-asserted-by":"publisher","first-page":"k4226","DOI":"10.1136\/bmj.k4226","volume":"363","author":"C Xu","year":"2018","unstructured":"Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018;363:k4226.","journal-title":"BMJ."},{"key":"632_CR33","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/phar.2035","volume":"37","author":"AK Ali","year":"2017","unstructured":"Ali AK, Watson DE. Pharmacovigilance assessment of immune-mediated reactions reported for checkpoint inhibitor cancer immunotherapies. Pharmacotherapy. 2017;37:1383\u201390.","journal-title":"Pharmacotherapy."},{"key":"632_CR34","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721\u20138.","journal-title":"JAMA Oncol."},{"key":"632_CR35","doi-asserted-by":"publisher","unstructured":"Ji HH, Tang XW, Dong Z, Song L, Jia YT. Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS. Clin Drug Investig. 2019. \n                  https:\/\/doi.org\/10.1007\/s40261-018-0735-0\n                  \n                .","DOI":"10.1007\/s40261-018-0735-0"},{"key":"632_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40264-015-0351-3","volume":"39","author":"MA Macia-Martinez","year":"2016","unstructured":"Macia-Martinez MA, de Abajo FJ, Roberts G, Slattery J, Thakrar B, Wisniewski AF. An empirical approach to explore the relationship between measures of disproportionate reporting and relative risks from analytical studies. Drug Saf. 2016;39:29\u201343.","journal-title":"Drug Saf"},{"key":"632_CR37","doi-asserted-by":"publisher","first-page":"175883591876462","DOI":"10.1177\/1758835918764628","volume":"10","author":"A Sosa","year":"2018","unstructured":"Sosa A, Lopez CE, Simon OC, Karachaliou N, Rosell R. Clinical assessment of immune-related adverse events. Ther Adv Med Oncol. 2018;10:1758835918764628.","journal-title":"Ther Adv Med Oncol."},{"key":"632_CR38","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/liv.13746","volume":"38","author":"DL Suzman","year":"2018","unstructured":"Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int. 2018;38:976\u201387.","journal-title":"Liver Int."},{"key":"632_CR39","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E De Martin","year":"2018","unstructured":"De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68:1181\u201390.","journal-title":"J Hepatol"},{"key":"632_CR40","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/ijc.30678","volume":"141","author":"W Wang","year":"2017","unstructured":"Wang W, Lie P, Guo M, He J. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data. Int J Cancer. 2017;141:1018\u201328.","journal-title":"Int J Cancer"},{"key":"632_CR41","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/annonc\/mdw649","volume":"28","author":"F Gelsomino","year":"2017","unstructured":"Gelsomino F, Vitale G, D\u2019Errico A, Bertuzzi C, Andreone P, Ardizzoni A. Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol. 2017;28:671\u20132.","journal-title":"Ann Oncol"},{"key":"632_CR42","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s00262-018-2159-3","volume":"67","author":"F Gelsomino","year":"2018","unstructured":"Gelsomino F, Vitale G, Ardizzoni A. Immune-mediated cholangitis: is it always nivolumab\u2019s fault? Cancer Immunol Immunother. 2018;67:1325\u20137.","journal-title":"Cancer Immunol Immunother"},{"key":"632_CR43","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs. 2017;35:529\u201336.","journal-title":"Invest New Drugs"},{"key":"632_CR44","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00262-017-2062-3","volume":"67","author":"J Kashima","year":"2018","unstructured":"Kashima J, Okuma Y, Shimizuguchi R, Chiba K. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother. 2018;67:61\u20135.","journal-title":"Cancer Immunol Immunother"},{"key":"632_CR45","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s10637-017-0484-6","volume":"36","author":"F Gelsomino","year":"2018","unstructured":"Gelsomino F, Vitale G, Ardizzoni A. A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event. Invest New Drugs. 2018;36:144\u20136.","journal-title":"Invest New Drugs"},{"key":"632_CR46","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hep.30189","volume":"69","author":"K Ogawa","year":"2018","unstructured":"Ogawa K, Kamimura K, Terai S. Anti-programmed cell death-1 immunotherapy-related secondary sclerosing cholangitis. Hepatology. 2018;69:914\u20136.","journal-title":"Hepatology"},{"key":"632_CR47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2018.11.021","volume":"107","author":"S Noda-Narita","year":"2019","unstructured":"Noda-Narita S, Mizuno S, Noguchi S, Watanabe K, Nakai Y, Koike K, et al. Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab. Eur J Cancer. 2019;107:93\u20136.","journal-title":"Eur J Cancer"},{"key":"632_CR48","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/hep.28967","volume":"65","author":"HL Bonkovsky","year":"2017","unstructured":"Bonkovsky HL, Kleiner DE, Gu J, Odin JA, Russo MW, Navarro VM, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology. 2017;65:1267\u201377.","journal-title":"Hepatology"},{"key":"632_CR49","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40801-018-0131-3","volume":"5","author":"T Misu","year":"2018","unstructured":"Misu T, Kortepeter CM, Munoz MA, Wu E, Dal Pan GJ. An evaluation of \u201cdrug ineffective\u201d postmarketing reports in drug safety surveillance. Drugs Real World Outcomes. 2018;5:91\u20139.","journal-title":"Drugs Real World Outcomes."},{"key":"632_CR50","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40264-015-0271-2","volume":"38","author":"K Juhlin","year":"2015","unstructured":"Juhlin K, Karimi G, Ander M, Camilli S, Dheda M, Har TS, et al. Using VigiBase to identify substandard medicines: detection capacity and key prerequisites. Drug Saf. 2015;38:373\u201382.","journal-title":"Drug Saf"},{"key":"632_CR51","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40264-016-0499-5","volume":"40","author":"ZA Trippe","year":"2017","unstructured":"Trippe ZA, Brendani B, Meier C, Lewis D. Identification of substandard medicines via disproportionality analysis of individual case safety reports. Drug Saf. 2017;40:293\u2013303.","journal-title":"Drug Saf"},{"key":"632_CR52","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bcp.13098","volume":"83","author":"P Inacio","year":"2017","unstructured":"Inacio P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol. 2017;83:227\u201346.","journal-title":"Br J Clin Pharmacol"},{"key":"632_CR53","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","volume":"23","author":"S Champiat","year":"2017","unstructured":"Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1. Clin Cancer Res. 2017;23:1920\u20138.","journal-title":"Clin Cancer Res"},{"key":"632_CR54","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33:3541\u20133.","journal-title":"J Clin Oncol"},{"key":"632_CR55","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","volume":"115","author":"K Sato","year":"2018","unstructured":"Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer. 2018;115:71\u20134.","journal-title":"Lung Cancer."},{"key":"632_CR56","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4:374\u20138.","journal-title":"JAMA Oncol."},{"key":"632_CR57","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","volume":"12","author":"S Teraoka","year":"2017","unstructured":"Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, et al. Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study. J Thorac Oncol. 2017;12:1798\u2013805.","journal-title":"J Thorac Oncol."},{"key":"632_CR58","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40261-017-0503-6","volume":"37","author":"C Michel","year":"2017","unstructured":"Michel C, Scosyrev E, Petrin M, Schmouder R. Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles? Clin Drug Investig. 2017;37:415\u201322.","journal-title":"Clin Drug Investig."},{"key":"632_CR59","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","volume":"4","author":"Y Oshima","year":"2018","unstructured":"Oshima Y, Tanimoto T, Yuji K, Tojo A. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol. 2018;4:1112\u20135.","journal-title":"JAMA Oncol."},{"key":"632_CR60","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579\u201389.","journal-title":"Lancet Oncol."},{"key":"632_CR61","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/TCRM.S137144","volume":"13","author":"A Arora","year":"2017","unstructured":"Arora A, Jalali RK, Vohora D. Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs. Ther Clin Risk Manag. 2017;13:1195\u2013203.","journal-title":"Ther Clin Risk Manag"},{"key":"632_CR62","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40264-017-0592-4","volume":"41","author":"G Trifiro","year":"2018","unstructured":"Trifiro G, Sultana J, Bate A. From big data to smart data for pharmacovigilance: the role of healthcare databases and other emerging sources. Drug Saf. 2018;41:143\u20139.","journal-title":"Drug Saf"},{"key":"632_CR63","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ejca.2017.09.007","volume":"86","author":"RE Kibbelaar","year":"2017","unstructured":"Kibbelaar RE, Oortgiesen BE, van der Wal-Oost AM, Boslooper K, Coebergh JW, Veeger NJGM, et al. Bridging the gap between the randomised clinical trial world and the real world by combination of population-based registry and electronic health record data: a case study in haemato-oncology. Eur J Cancer. 2017;86:178\u201385.","journal-title":"Eur J Cancer"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-019-00632-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-019-00632-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-019-00632-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T21:09:18Z","timestamp":1600549758000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-019-00632-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,29]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4,1]]}},"alternative-id":["632"],"URL":"https:\/\/doi.org\/10.1007\/s11523-019-00632-w","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,29]]},"assertion":[{"value":"29 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to assist in the preparation of this study. Authors at the University of Bologna (ER, EP, FDP) are supported by Institutional Research Funds (Ricerca Fondamentale Orientata).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Emanuel Raschi, Alessandra Mazzarella, Ippazio Cosimo Antonazzo, Nicol\u00f2 Bendinelli, Emanuele Forcesi, Marco Tuccori, Ugo Moretti, Elisabetta Poluzzi, and Fabrizio De Ponti declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}